Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dermata Therapeutics, Inc.DRMA · Entity 8182 | SVP, CFO | August 16, 2026 | August 18, 2026 |
| Turning Point Therapeutics, Inc.TPTX · Entity 124461 | Principal Accounting Officer | May 14, 2021 | May 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dermata Therapeutics, Inc.
Report date August 16, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 232,463 |
Reported balance
After 2026-08-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-16 · Grant · Acquired 102,040 · Balance 232,463 F1: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock. F2: The purchase price per share of common stock and accompanying warrants was $1.47. F3: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. |
| Series E Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 | Direct | 102,040 |
Reported balance
After 2026-08-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-16 · Grant · Acquired 102,040 · Balance 102,040 F1: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock. F2: The purchase price per share of common stock and accompanying warrants was $1.47. F3: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. |
| Series F Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 | Direct | 102,040 |
Reported balance
After 2026-08-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-16 · Grant · Acquired 102,040 · Balance 102,040 F1: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock. F2: The purchase price per share of common stock and accompanying warrants was $1.47. F4: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock.
F2: The purchase price per share of common stock and accompanying warrants was $1.47.
F3: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
F4: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
Turning Point Therapeutics, Inc.
Report date May 14, 2021 · Filed May 14, 2021
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 16, 2026 Filed Aug 18, 2026 21:21 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantSeries F Warrant (Right to Buy) · Derivative | 102,040 | Not disclosed Strike: $1.47 | Not disclosed |
DisclosureSEC source: 0001493152-26-039046 · ownership.xml · derivative · entry 3 Van Hoose Kyri K. · CIK 0001860885 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,040 Underlying: Common Stock · 102,040 shares Expires not disclosed F1 · kind: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock. F2 · price: The purchase price per share of common stock and accompanying warrants was $1.47. F4 · derivative.exercise_date: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. F4 · derivative.expiration_date: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. Read SEC document |
| August 16, 2026 Filed Aug 18, 2026 21:21 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantSeries E Warrant (Right to Buy) · Derivative | 102,040 | Not disclosed Strike: $1.47 | Not disclosed |
DisclosureSEC source: 0001493152-26-039046 · ownership.xml · derivative · entry 2 Van Hoose Kyri K. · CIK 0001860885 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,040 Underlying: Common Stock · 102,040 shares Expires not disclosed F1 · kind: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock. F2 · price: The purchase price per share of common stock and accompanying warrants was $1.47. F3 · derivative.exercise_date: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. F3 · derivative.expiration_date: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. Read SEC document |
| August 16, 2026 Filed Aug 18, 2026 21:21 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantCommon Stock | 102,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-039046 · ownership.xml · nonDerivative · entry 1 Van Hoose Kyri K. · CIK 0001860885 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,463 F1 · kind: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock. F2 · price: The purchase price per share of common stock and accompanying warrants was $1.47. F3 · balance_after: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001493152-26-000701 · ownership.xml · derivative · entry 1 Van Hoose Kyri K. · CIK 0001860885 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 00:53 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantWarrant (Right to Buy) · Derivative | 7,874 | Not disclosed Strike: $2.04 | Not disclosed |
DisclosureSEC source: 0001493152-25-029470 · ownership.xml · derivative · entry 5 Van Hoose Kyri K. · CIK 0001860885 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,874 Underlying: Common Stock · 7,874 shares Expires not disclosed F6 · kind: In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the "old" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act. F3 · shares: Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025. F6 · price: In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the "old" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act. F6 · derivative.exercise_date: In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the "old" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act. F6 · derivative.expiration_date: In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the "old" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act. F3 · derivative.underlying_shares: Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025. F3 · balance_after: Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 00:53 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | Disposition to issuerWarrant (Right to Buy) · Derivative | 7,874 | Not disclosed Strike: $12.70 | Not disclosed |
DisclosureSEC source: 0001493152-25-029470 · ownership.xml · derivative · entry 4 Van Hoose Kyri K. · CIK 0001860885 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,874 shares Expires not disclosed F6 · kind: In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the "old" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act. F3 · shares: Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025. F6 · price: In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the "old" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act. F6 · derivative.exercise_date: In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the "old" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act. F6 · derivative.expiration_date: In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the "old" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act. F3 · derivative.underlying_shares: Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 00:53 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantSeries D Warrant (Right to Buy) · Derivative | 122,549 | Not disclosed Strike: $2.04 | Not disclosed |
DisclosureSEC source: 0001493152-25-029470 · ownership.xml · derivative · entry 3 Van Hoose Kyri K. · CIK 0001860885 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,549 Underlying: Common Stock · 122,549 shares Expires not disclosed F1 · kind: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04. F2 · price: The purchase price per share of common stock and accompanying warrants was $2.04. F5 · derivative.exercise_date: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. F5 · derivative.expiration_date: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 00:53 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantSeries C Warrant (Right to Buy) · Derivative | 122,549 | Not disclosed Strike: $2.04 | Not disclosed |
DisclosureSEC source: 0001493152-25-029470 · ownership.xml · derivative · entry 2 Van Hoose Kyri K. · CIK 0001860885 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,549 Underlying: Common Stock · 122,549 shares Expires not disclosed F1 · kind: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04. F2 · price: The purchase price per share of common stock and accompanying warrants was $2.04. F4 · derivative.exercise_date: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. F4 · derivative.expiration_date: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 00:53 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantCommon Stock | 122,549 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-25-029470 · ownership.xml · nonDerivative · entry 1 Van Hoose Kyri K. · CIK 0001860885 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,423 F1 · kind: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04. F2 · price: The purchase price per share of common stock and accompanying warrants was $2.04. F3 · balance_after: Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 22:03 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantWarrant (Right to Buy) · Derivative | 78,741 | Not disclosed Strike: $1.27 | Not disclosed |
DisclosureSEC source: 0001654954-25-000692 · section16.xml · derivative · entry 2 Van Hoose Kyri K. · CIK 0001860885 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,741 Underlying: Common Stock · 78,741 shares Expires not disclosed F1 · kind: The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The purchase price per share of Common Stock and accompanying Warrant was $1.27. F3 · derivative.exercise_date: The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants issued in the private placement. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. F3 · derivative.expiration_date: The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants issued in the private placement. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 22:03 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantCommon Stock | 78,741 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-25-000692 · section16.xml · nonDerivative · entry 1 Van Hoose Kyri K. · CIK 0001860885 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,741 F1 · kind: The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The purchase price per share of Common Stock and accompanying Warrant was $1.27. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 23:50 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001654954-25-000399 · section16.xml · derivative · entry 1 Van Hoose Kyri K. · CIK 0001860885 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-01-12 F1 · derivative.exercise_date: (1) The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date. Read SEC document |
| January 04, 2024 Filed Jan 6, 2024 02:00 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001654954-24-000291 · section16.xml · derivative · entry 1 Van Hoose Kyri K. · CIK 0001860885 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-01-03 F1 · derivative.exercise_date: The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001654954-23-000147 · section16.xml · derivative · entry 1 Van Hoose Kyri K. · CIK 0001860885 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:15 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000905718-22-000050 · dermata_fm4jan32022.xml · derivative · entry 1 Van Hoose Kyri K. · CIK 0001860885 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The option will vest as to 40% upon the 12 month anniversary of the grant date, and will vest as to 60% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 00:32 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to Buy) · Derivative | 75,000 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0000905718-21-001165 · dermata_fm4sep121.xml · derivative · entry 1 Van Hoose Kyri K. · CIK 0001860885 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-09-01 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments commencing October 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.